Featured Articles

Simcere Pharmaceutical Group Ltd. and Boehringer Ingelheim have entered into a global license and collaboration agreement to develop SIM0709, a pre-clinical bispecific antibody designed…
Read More...

Eisai Co., Ltd. and Biogen Inc. have announced a key regulatory milestone for their Alzheimer’s disease therapy lecanemab-irmb, marketed in the United States as LEQEMBI®. The U.S. Food…
Read More...

China’s National Medical Products Administration (NMPA) has approved ENHERTU® (trastuzumab deruxtecan) for the treatment of adult patients with locally advanced or metastatic…
Read More...

Charles River Laboratories International and Gazi University Faculty of Medicine have entered into a strategic collaboration aimed at advancing gene therapy research for rare genetic…
Read More...

Novo Nordisk and Aspect Biosystems have announced the expansion of their strategic partnership, entering a new phase focused on developing advanced cellular medicines for diabetes that…
Read More...

Bristol Myers Squibb (BMS) has entered into a strategic collaboration with Microsoft to accelerate the early detection of lung cancer by integrating advanced artificial intelligence…
Read More...

SciNeuro Pharmaceuticals has entered into a worldwide licensing and collaboration agreement with Novartis Pharma AG to advance a novel antibody program for the treatment of Alzheimer’s…
Read More...

AbbVie and West Pharmaceutical Services have announced a definitive agreement under which AbbVie will acquire a device manufacturing facility and associated intellectual property from…
Read More...

Solid Biosciences Inc., a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has reached two important milestones in the…
Read More...

GSK plc has reported positive results from two pivotal phase III clinical trials evaluating bepirovirsen, an investigational antisense oligonucleotide therapy for chronic hepatitis B…
Read More...

Takeda Pharmaceutical Company has entered into a global collaboration and license agreement with Halozyme Therapeutics to use Halozyme’s proprietary ENHANZE® drug delivery technology…
Read More...

The US Food and Drug Administration (FDA) has accepted for priority review a supplemental biologic license application (sBLA) for Tzield (teplizumab-mzwv), a therapy designed to delay…
Read More...

Takeda and Protagonist Therapeutics have submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults…
Read More...

GSK has received U.S. Food and Drug Administration approval for Exdensur (depemokimab-ulaa), a new add-on maintenance treatment for patients aged 12 years and older with severe asthma…
Read More...

Astellas Pharma and Pfizer have reported positive topline results from an interim analysis of the Phase 3 EV-304 clinical trial, strengthening evidence that the combination of PADCEV™…
Read More...

Takeda Pharmaceutical Company has announced positive topline results from two pivotal Phase 3 clinical trials evaluating zasocitinib (TAK-279), a next-generation oral therapy for adults…
Read More...

Johnson & Johnson has secured U.S. Food and Drug Administration approval for RYBREVANT FASPRO™, marking a significant advance in the treatment of epidermal growth factor receptor…
Read More...

China’s National Medical Products Administration (NMPA) has approved JASCAYD® (nerandomilast), marking the first new treatment for adults with progressive pulmonary fibrosis (PPF) in…
Read More...

China’s National Medical Products Administration (NMPA) has approved two innovative Sanofi therapies—Qfitlia (fitusiran) for hemophilia and Cablivi (caplacizumab) for acquired…
Read More...

Pfizer has released compelling new data from its Phase 3 HER2CLIMB-05 clinical trial, showing that the company’s tyrosine kinase inhibitor, TUKYSA® (tucatinib), significantly improved…
Read More...